- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Suwanee Today
By the People, for the People
SANUWAVE Health Shares Drop Below 50-Day Average
Investors question whether it's time to sell the medical technology stock.
Published on Mar. 6, 2026
Got story updates? Submit your updates here. ›
Shares of SANUWAVE Health, Inc. (OTCMKTS:SNWV), a medical technology company focused on non-invasive shockwave therapy devices, have fallen below their 50-day moving average, raising concerns among investors about the stock's performance.
Why it matters
SANUWAVE's shockwave therapy products are designed to address chronic and hard-to-heal conditions, including diabetic foot ulcers and other wounds. The company's stock performance is closely watched as an indicator of investor sentiment around its technology and market potential.
The details
SANUWAVE Health's shares traded as low as $23.03 on Tuesday, below the company's 50-day moving average of $26.97. The stock closed at $23.63, with a trading volume of 51,253 shares. SANUWAVE has a market capitalization of $198.62 million and a price-to-earnings ratio of 2.78.
- SANUWAVE Health's shares crossed below their 50-day moving average during trading on Tuesday.
The players
SANUWAVE Health, Inc.
A medical technology company focused on the development and commercialization of non-invasive, extracorporeal shockwave therapy devices, headquartered in Suwanee, Georgia.
The takeaway
The drop in SANUWAVE Health's stock price below its 50-day moving average raises questions about the company's near-term performance and the market's confidence in its shockwave therapy technology. Investors will be closely watching the stock's movements in the coming days and weeks to gauge the company's long-term prospects.


